President & Chief Executive Officer
Gerri Henwood has served as our President and Chief Executive Officer and a director of the Company since our inception in 2008. Ms. Henwood also serves as Chief Executive Officer and a director of the company of Baudax Bio, Inc. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Ms. Henwood continues to spend a very small portion of her time engaged in the provision of consulting services for MCG to other companies, including companies that are engaged in the development and commercialization of other pharmaceutical products. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization. IBAH reached a net revenue level of $150 million, as a NASDAQ traded company, before being acquired by Omnicare in 1998. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc, in the pharmaceutical management program. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division. Ms. Henwood currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, a position she has held since May 2015, and two private companies, and she previously served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015. Ms. Henwood also serves on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc. Ms. Henwood holds a B.S. in Biology from Neumann University. As our founder and having served as a director since our inception, Ms. Henwood’s extensive knowledge of our business and history, experience as a board member of multiple publicly-traded and privately-held companies, and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies, as well as Ms. Henwood’s strong background in clinical and product development and substantial knowledge of the pharmaceutical industry, contributed to our Board’s conclusion that she should serve as a director of our company.
Ryan D. Lake
Chief Financial Officer
Mr. Lake has served as our Chief Financial Officer since January 2018 and he has over 20 years of senior financial and life sciences leadership experience. Mr. Lake joined Recro in June 2017 as the Company's Chief Accounting Officer and Senior Vice President of Finance. Mr. Lake also serves as Chief Financial Officer of Baudax Bio, Inc. Prior to joining Recro, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privately-held, commercial-stage, medical device company. From 2012 to 2015, Mr. Lake held executive management and senior finance positions, including Director of the Natural Materials Division, Controller and Senior Director of Finance, at DSM Biomedical (successor to Kensey Nash after its acquisition in 2012), a division of Royal DSM (listed on Euronext Amsterdam), a global science-based company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake held various senior financial positions of increasing responsibility, most notably Senior Director of Finance and Interim CFO, with Kensey Nash Corporation, a Nasdaq-listed, medical device company. Earlier in his career, Mr. Lake worked at Deloitte & Touche, LLP. Mr. Lake is a Certified Public Accountant, Chartered Global Management Accountant and holds a B.S. degree in Accounting from West Chester University of Pennsylvania.
Scott Rizzo, MBA, MMM
Executive Vice President and General Manager
Scott Rizzo brings more than 25 years of leadership experience and operational excellence to Recro Gainesville as the site’s executive vice president and general manager. Rizzo joined Recro in 2015 and has been instrumental in developing a client-focused culture at the Georgia-based CDMO. With full profit and loss (P&L) responsibility of the CDMO business, Rizzo drives strategic initiatives to yield continued business growth while prioritizing employee development and community relations through engagements with the Greater Hall Chamber of Commerce and Georgia Bio.
Prior to joining Recro Gainesville, Rizzo held various leadership positions in both large and small pharmaceutical businesses and consulting organizations, including Roche Pharmaceuticals, Barrier Therapeutics, J. Knipper, DuPont, and PricewaterhouseCoopers.
Rizzo is a graduate of Pennsylvania State University, where he earned both his master’s of business administration and master’s of manufacturing management degrees. He is currently a board member of Georgia Bio and formerly a member of the Rutgers University Graduate Center for Supply Chain Management and the alumni advisory board for Pennsylvania State University.